Day: May 4, 2023

Deriv’s new office locations in 2022

In 2022, Deriv opened 2 new offices in Asia, 2 in Europe, and one each in South America, Oceania, and the Caribbean.

CYBERJAYA, Malaysia, May 04, 2023 (GLOBE NEWSWIRE) — Deriv, one of the world’s largest online brokers, opened 7 new offices worldwide in 2022 to broaden its reach and leverage talented professionals spread across the globe.

In the fast-moving world of financial trading, changes are inevitable. Trading firms need to adapt to the evolving financial environment and innovate on their feet. Deriv has always been a broker able to adapt to changes. Last year was one of success and expansion for the firm, reflected in its opening of 7 new offices worldwide.

Deriv’s new office locations ranged from Vanuatu in the east to the Cayman Islands in the west and spanned 3 continents. Deriv opened 2 new offices in Asia, 2 in Europe, and one each in South America, Oceania, and the Caribbean.

Singapore and Amman, Jordan, became Deriv’s latest offices in Asia. Reading, UK, and Berlin, Germany, were the European additions to Deriv workplaces. A new office was set up in Ciudad del Este, Paraguay, making it the company’s second workplace in the country, adding to its existing address in Asunción. George Town, Cayman Islands, and Port Vila, Vanuatu, were the other Deriv workplaces in 2022.

The latest additions take the total Deriv office count up to 20 in 16 countries and will help the company reach new clients in more locations as it looks to become the world’s number 1 trading provider.

As it expands globally, Deriv aims to tap into the vast talent pool that exists across the world and provide its employees with the best tools to enhance their knowledge, skills, and experience which will in turn enable them to contribute to the company’s growth and success. Several Deriv locations have been certified with the ‘Best Places to Work’ for 2022 by Great Place to Work® (GPTW).

Jean-Yves Sireau, the CEO of Deriv, said: “At Deriv, we believe that talent isn’t restricted by geography. Our 7 new offices have allowed us to explore new markets — some of them in non-English-speaking countries — and hire quality professionals to help us achieve our goals in 2023. We are expanding our reach by adding new products and services, and customising them to local needs as we integrate our systems with AI language tools, including Amazon Translate.”

He added: “Our hires at the new offices have helped us strengthen our technical infrastructure, add expertise, and create localised educational materials for traders on our platforms.”

Over the course of 2023, Deriv will look to add new employees at its latest offices and to its existing multinational and multicultural workforce — that currently stands at over 1,200 — as it aims to become the world’s number 1 trading provider. If you want to be part of this successful and fast-growing team, check out open positions at Deriv.

About Deriv

Starting its journey in 1999, Deriv’s mission has been to make online trading accessible to anyone, anywhere. Deriv’s product offering includes intuitive trading platforms, over 200 tradable assets (in markets such as forex, stocks, and cryptocurrencies), unique trade types, and more. With more than 1,200 employees in 20 global offices spread across 16 countries, Deriv strives to provide the best work environment, which includes positive work culture, timely addressing of employee concerns, celebrating achievements, and conducting initiatives to boost their morale.

PRESS CONTACT
Aleksandra Zuzic
aleksandra@deriv.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c41b1ae9-345e-4315-a55e-62d7dc21ad3a

GlobeNewswire Distribution ID 1000808216

Zoom aims to empower the India workforce with the rollout of Zoom Phone

SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Today, Zoom (NASDAQ: ZM) announced that it has received the Unified License with Access – All/PAN India, NLD National Long Distance, and ILD – International Long Distance from the Department of Telecommunications (DoT), Government of India. With these licenses, the company will be able to offer Zoom Phone, its industry leading cloud PBX service, to multinational corporations (MNCs) and businesses operating in India.

Zoom Phone is a global cloud PBX application service, enabling MNCs and businesses in India to have a single communication platform for their global workforce. Zoom partners with international telecommunication providers and offers phone numbers and calling plans in 47 countries and territories bundled with cloud PBX service, making it simple for customers to deploy and manage their phone services.

Zoom Phone offers a robust set of features for the modern workforce, including intelligent call routing, auto attendants, interactive voice response, shared line appearance, call queuing, call analytics, voicemail, recordings and transcriptions, desktop/mobile app experience optimized for business users and integrations with CRM applications.

“We are thrilled and proud to receive the unified licenses from the Department of Telecommunications. With Zoom Phone, India businesses and multinational corporations can support hybrid work environments, foster greater collaboration among employees and elevate the customer experience,” said Abe Smith, Head of International, Zoom. “This important milestone underscores our continued focus in countries like India, a strategic growth market for Zoom, and our commitment to bringing new and innovative collaboration solutions to our customers.”

Zoom Phone grew more than 100% year over year globally in fiscal year 2023, surpassing 5.5 million seats in the fourth quarter of fiscal year 2023. This is a testament to Zoom Phone’s ability to meet customer requirements for simplicity and flexibility and help businesses transition to a modern cloud communications platform.

In the coming months, Zoom will be working with regulators and partners in India to offer a complete telecommunications service bundled with its Zoom Phone PBX service.

“Feeling the pinch to produce more with less, Indian multinationals are increasingly turning to collaboration platforms including video communications to streamline workflows and engage employees, partners as well as their customers. The launch of Zoom Phone will offer a competitive edge to the collaboration solution vendor in targeting the Indian enterprise customers,” said Nikhil Batra, Research Director, Telecom at IDC. “Collaboration solutions have been highlighted by Indian enterprises as their top ICT investment priority through the course of 2023 and Zoom Phone, along with the broader Zoom collaboration portfolio, could help organizations accelerate this move to support and empower an increasingly mobile and connected workforce.”

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
press@zoom.us

GlobeNewswire Distribution ID 8831836

SYDNEY, May 04, 2023 (GLOBE NEWSWIRE) — George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing its full-service clinical research organization (CRO) expertise for the Hummingbird Bioscience-sponsored trials.

Molecular-matched therapies have revolutionized cancer treatment with the capability to inhibit specific molecular targets leading to better therapeutic responses and less system toxicity. Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing biologic medicines for hard-to-treat diseases, is bringing its clinical-stage anti-HER3 drug known as HMBD-001 into molecular-matched patient trials in Australia for the first time.

Early phase clinical trials are primarily designed to evaluate the safety and tolerability of a new therapy as well as to identify a suitable dose for further evaluation. However, historically any preliminary efficacy data generated has been considered only as suggestive and requires further exploration in larger later phase trials. As molecular-based therapies have evolved, it is common to see significant antitumor activity when targeted agents are tested on molecularly selected populations in early drug development. Signaling pathways and molecular networks are known for their critical roles in driving and controlling cellular processes and are therefore linked to the onset of cancer, as well as its potential treatment. The development of agents targeting these pathways and networks is a key piece in the ongoing advancement of molecular-matched therapy and its advancement to provide better patient outcomes.

Developed with Hummingbird Bioscience’s Rational Antibody Discovery platform, HMBD-001 is a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3. This gives HMBD-001 a novel mechanism of action via preventing HER3 dimerization and activation regardless of NRG1 binding. Preclinical models have shown that HMBD-001 potently inhibits the activation of the MAPK/PI3K signaling pathway and consequently, prevents tumor growth and drug resistance.

“We are thrilled to be able to partner with Hummingbird Bioscience and several well regarded Australian clinical trial sites to avail Australian cancer patients with this precision therapy where hopefully ‘cancer meets its match.’ George Clinical’s expertise enables our clients to move through the regulation process to quick start-up and helps them think through their early phase trial strategies, site selections and operational models,” said George Clinical Early Phase Global Head, Gillian Ryan.

Coupled with its experience in conducting more than 300 oncology studies across the globe, as well as its established robust network of practicing medical oncologists with expertise across a range of tumor types and the latest immunotherapies, George Clinical has a deep and well-regarded history in the conduct of early phase studies. The organization’s success with trials of this type has been driven by scientific expertise and operational excellence. Using the combination of scientific leadership and local knowledge, the oncology trials conducted by George Clinical maintain their focus on the trials’ scientific objective while maximizing trial conduct expertise to enable the best result possible.

“By providing access to some of the world’s most experienced medical, scientific, and operational teams in oncology research, George Clinical is uniquely placed to partner with us to meet the complex and specialized demands of these early phase trials in Australia,” said Jerome Boyd-Kirkup, Ph.D., chief scientific officer, Hummingbird Bioscience.

Matthew Reabold
George Clinical
760-645-0496
mreabold@georgeclinical.com

GlobeNewswire Distribution ID 8831407

COPENHAGEN, Denmark and HAMBURG, Germany, May 04, 2023 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners, on behalf of its Flagship Funds, today announced that it has launched Baldur Power GmbH as its dedicated platform for the development and realisation of renewable energy projects in Germany.

“As part of CIP’s dedicated strategy of investing in growth platforms, we are excited about the prospects of Baldur Power and the opportunity to create, over time, an established developer and owner of renewable energy projects in Germany,” said Radu Gruescu, Partner at CIP.

Baldur is a recently established company and will primarily focus on the origination, development and implementation of solar PV, onshore wind, and battery storage projects. In addition to project development, Baldur’s capabilities comprise planning, procurement, logistics, engineering, and construction management. Based in Hamburg, the company maintains an in-house fleet of equipment critical for the realisation of solar PV projects.

CIP’s Flagship Funds will initially provide capital for project development and for the growth of Baldur Power and then, subject to investment decisions at the time, CIP intends to provide the capital required for the construction of the projects developed by the company, thus establishing Baldur as an independent power producer that owns both operational projects and a growing pipeline of projects under construction and in development.

“With capabilities to manage the development and construction of its own projects and, where appropriate, in cooperation with partners too, Baldur is well positioned to become an Independent Power Producer with an attractive portfolio of renewable energy projects, and we look forward to supporting this growth trajectory,” said CIP partner Radu Gruescu.

Watson Farley & Williams LLP acted as legal advisor to CIP.

More information is available at baldur-power.de

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages ten funds and has to date raised approximately EUR 19 billion for investments in energy and associated infrastructure from more than 140 international institutional investors. CIP has approximately 400 employees and 11 offices around the world. For more information, visit www.cip.com.

For further information, please contact:

Copenhagen Infrastructure Partners
Oliver Routhe Skov, Head of Media Relations
Phone: +45 30541227
Email: orsk@cisc.dk

Thomas Kønig, Partner – Investor Relations
Phone: +45 7070 5151
Email: tkon@cip.dk

GlobeNewswire Distribution ID 1000808194